Next Generation
Gene Therapies

About G2 BIO

Founded in mid-2021 by the University of Pennsylvania Gene Therapy Program, James Wilson, M.D., Ph.D., Tachi Yamada, M.D. and Temasek.

$200M in initial financing
from Temasek

Formed to discover, translate and greatly accelerate the development of a large portfolio of transformative genetic-based therapies

Opportunity to bring multiple drugs into the clinic by 2026

Corporate structure designedto optimize capital use to generate multiple value inflection milestones

Leadership

James Wilson M.D., Ph.D.

James Wilson M.D., Ph.D.

Scientific Chair, Co-founder

Ramon Salsas Escat, Ph.D.

Ramon Salsas Escat, Ph.D.

SVP of Business Development

Matt Wilson

Matt Wilson

Portfolio Manager, Co-founder

Joint Steering Committee

Khoo Shih, Ph.D.

Managing Director, Temasek

Stephen Oesterle, M.D.

Corporate Advisor, Temasek

Press Releases

09/01/2021

Press Release Goes Here. Excepteur Sint Occaecat Cupidatat Non Proident Excepteur Sint Occaecat Cupidatat Non.

09/01/2021

Press Release Goes Here. Excepteur Sint Occaecat Cupidatat Non Proident Excepteur Sint Occaecat Cupidatat Non.

09/01/2021

Press Release Goes Here. Excepteur Sint Occaecat Cupidatat Non Proident Excepteur Sint Occaecat Cupidatat Non.

09/01/2021

Press Release Goes Here. Excepteur Sint Occaecat Cupidatat Non Proident Excepteur Sint Occaecat Cupidatat Non.